MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted

Total Page:16

File Type:pdf, Size:1020Kb

MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List The agents listed below are the antihistamine/decongestant drug products listed in the Mississippi Medicaid Preferred Drug List (PDL). This is a cross-reference between the drug product name and its active ingredients to reference the antihistamine/decongestant portion of the PDL. For more information concerning the PDL, including non- preferred agents, the OTC formulary, and other specifics, please visit our website at www.medicaid.ms.gov. List Effective 07/16/10 Therapeutic Class Active Ingredients Preferred Non-Preferred ANTIHISTAMINES - 1ST GENERATION BROMPHENIRAMINE MALEATE BPM BROMAX BROMPHENIRAMINE MALEATE J-TAN PD BROMSPIRO LODRANE 24 LOHIST 12HR VAZOL BROMPHENIRAMINE TANNATE BROMPHENIRAMINE TANNATE J-TAN P-TEX BROMPHENIRAMINE/DIPHENHYDRAM ALA-HIST CARBINOXAMINE MALEATE CARBINOXAMINE MALEATE PALGIC CHLORPHENIRAMINE MALEATE CHLORPHENIRAMINE MALEATE CPM 12 CHLORPHENIRAMINE TANNATE ED CHLORPED ED-CHLOR-TAN MYCI CHLOR-TAN MYCI CHLORPED PEDIAPHYL TANAHIST-PD CLEMASTINE FUMARATE CLEMASTINE FUMARATE CYPROHEPTADINE HCL CYPROHEPTADINE HCL DEXCHLORPHENIRAMINE MALEATE DEXCHLORPHENIRAMINE MALEATE DIPHENHYDRAMINE HCL ALLERGY MEDICINE ALLERGY RELIEF BANOPHEN BENADRYL BENADRYL ALLERGY CHILDREN'S ALLERGY CHILDREN'S COLD & ALLERGY COMPLETE ALLERGY DIPHEDRYL DIPHENDRYL DIPHENHIST DIPHENHYDRAMINE HCL DYTUSS GENAHIST HYDRAMINE MEDI-PHEDRYL PHARBEDRYL Q-DRYL QUENALIN SILADRYL SILPHEN DIPHENHYDRAMINE TANNATE DIPHENMAX DOXYLAMINE SUCCINATE DOXYTEX ALDEX AN PYRILAMINE MAL/DEXBROMPHEN TAN POLY TAN TRIPROLIDINE HCL TRIPOHIST TRIPROLIDINE HCL 1ST GEN ANTIHISTAMINE & BROMPHENIR/DIPHENHYD/PHENYLEPH ALA-HIST D DECONGESTANT COMBINATIONS PE TAN/PYRIL MAL/DEXBROMPH TAN POLY TAN D PE/PE & PYRILAMINE TANNATE/CPM PHENA-S 12 P-EPD TAN/BROMPHENIRAMIN B-VEX PD BROVEX PD LODRANE D P-EPD TAN/CHLOR-TAN DICEL SUDAL 12 P-EPHED HCL/BROMPHENIRAMIN BPM PSEUDO BROMFENEX BROMHIST BROMFENEX-PD BROMHIST-NR HISTEX SR BROMPHENIRAMINE-PSEUDOEPHEDRI J-TAN D PD BROVEX PSB BROVEX PSE LODRANE LODRANE 24D LOHIST 12D LOHIST-PD PSE BPM RESPAHIST SILDEC Brand names are designated in bold in the drug product name column; all other agents are considered generic products. MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List P-EPHED HCL/D-BROMP MAL CONEX DISOPHROL Active Ingredient Abbreviation Key BROMPH=brompheniramine DEXBROMPH=dexbrompheniramine MAL=maleate P-EPD=pseudoephedrine CPM=chlorpheniramine maleate DEXCHLOR=dexchlorpheniramine METHSCOP=methscopolamine PYR=pyrilamine CPT=chlorpheniramine tannate DIPH=diphenhydramine PE=phenylephrine TAN=tannate Brand names are designated in bold in the drug product name column; all other agents are considered generic products. MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List Therapeutic Class Active Ingredients Preferred Non-Preferred 1ST GEN ANTIHISTAMINE & P-EPHED HCL/TRIPROLIDINE HCL PEDIATEX TD HIST-PSE DECONGESTANT COMBINATIONS TRIPOHIST D TRIP-PSE (Continued) P-EPHED SUL/D-BROMP MAL DISOPHROL DRIXORAL PHENYLEPHRINE HCL/CHLOR-MAL C-PHEN DROPS 10PEH-4CPM C-PHEN SYRUP ALERSULE DALLERGY-JR CENTERGY RESCON-JR CERON TUSSANIL CP DEC DALLERGY ED A-HIST MAXICHLOR PEH NASOHIST NOHIST PD-HIST D PHENYLEPH-CHLORPHEN RONDEC SILDEC-PE SONAHIST PHENYLEPHRINE HCL/PROMETH HCL PROMETHAZINE VC PHENYLEPHRINE/BROMPHENIRAMINE BROM TANN-PE TANN BROMFED BROMPHENIRAMINE-PHENYLEPHRINE BROMFED-PD BROVEX ADT ENTRE-B BROVEX PEB J-TAN D C-TAN D SERADEX-LA C-TAN D PLUS VAZOBID PHENYLEPHRINE-BROMPHENIRAMIN VAZOTAB RESPAHIST-II ZOTEX-PE PHENYLEPHRINE/CHLOR-TAN ALLANTAN ALLERX ED CHLORPED D DALLERGY-JR PE TANN-CP TANN MYCI CHLORPED D PEDIAPHYL D NY-TANNIC R-TANNA PHENYLEPH-CHLORPHEN PEDIATRIC R-TANNA PEDIATRIC TANAHIST D RYNATAN TANNATE RYNATAN PEDIATRIC PE/DIPH ALAHIST LQ PHENYLEPHRINE/DP-HYDRAM TAN D-TANN DIPHENMAX D PHENYLEPHRINE/P-TLOX CI/CP PHENYLTOLOXAMINE PE CPM RHINACON A PHENYLEPHRINE/PYRIL MAL/CP MYHIST-PD PHENA-PLUS RU-HIST FORTE PHENA-S TRIPLEX AD POLY HIST FORTE POLY HIST PD PYRICHLOR PE PHENYLEPHRINE/PYRILAMINE TAN ALLANVAN-S CHLOR-TAN A 12 R-TANNAMINE DECONSAL CT RYNESA 12S RYNA-12 RY-T-12 RYNA-12 S TRI-HIST PSEUDOEPHED TAN/DEXCHLOR TAN ALLERDUR PSEUDOEPHED TAN/PYRILAMINE TAN VIRAVAN-P PSEUDOEPHEDRINE HCL/CHLOR-MAL COLFED-A 60PSE-4CPM CPM PSE ACCUHIST DECONAMINE CPM-PSE DECONAMINE SR DURATUSS DA LOHIST-D GENAPHED PLUS NEUTRAHIST HISTEX PSE-CPM MAXICHLOR PSE PSEUDOEPHEDRINE-CHLORPHENIRAM SUDOGEST COLD & ALLERGY SUDAHIST TIBAMINE LA Active Ingredient Abbreviation Key BROMPH=brompheniramine DEXBROMPH=dexbrompheniramine MAL=maleate P-EPD=pseudoephedrine CPM=chlorpheniramine maleate DEXCHLOR=dexchlorpheniramine METHSCOP=methscopolamine PYR=pyrilamine CPT=chlorpheniramine tannate DIPH=diphenhydramine PE=phenylephrine TAN=tannate Brand names are designated in bold in the drug product name column; all other agents are considered generic products. MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List Therapeutic Class Active Ingredients Preferred Non-Preferred ANTIHISTAMINES- FIRST CHLOR-MAL/PHENYLEPH/METHSCOP ALLERGY DN PE ALLERX PE GENERATION/DECONGESTANT/ CHLOR-MES DALLERGY PE ANTICHOLINERGIC COMBINATIONS CHLOR-MES D HISTA-VENT DA DALLERGY RESCON DEHISTINE DURADRYL DURADRYL SR HISTATAB PH NOHIST-PE NOHIST-PLUS NOHIST-PLUS JR PCM PHENYLEPHRINE CM PREHIST D RESCON-MX SCOPOHIST SCOPOHIST-PE TRIALL CPM & PE TANNATES/METHSCOP NIT DURATAN PE P-EPHED HCL/CHLOR-MAL/BELL ALK RU-TUSS RESPA A.R. DEXCHLORPH/P-EPHED HC/METHSCOP CORYZA-D D-HIST D HISTATAB D PHENYLEPH/DEXCHLOR/METHSCOPOL DEXPHEN M RE-DRYLEX PSEUDOEPH/METHSCOP/CPM/PE ALLERX 10 ALLERX 30 PSEUDOEPHEDRINE/CPM/METHSCOPOL COLDAMINE DALLERGY PSE HISTATAB HISTA-VENT PSE SCOPOHIST TIME-HIST QD VISRX DECONGESTANT-ANTICHOLINERGIC P-EPHED HCL/METHSCOPOLAMN AMDRY-D ALLERX-D COMBINATIONS RESPIVENT-D SUDATRATE 1ST GEN ANTIHISTAMINE- DECONGESTANT-ANALGESIC COMB PHENYLEPH/ACETAMINOP/P-TLOX/CP TRITAL SR NOREL SR Active Ingredient Abbreviation Key BROMPH=brompheniramine DEXBROMPH=dexbrompheniramine MAL=maleate P-EPD=pseudoephedrine CPM=chlorpheniramine maleate DEXCHLOR=dexchlorpheniramine METHSCOP=methscopolamine PYR=pyrilamine CPT=chlorpheniramine tannate DIPH=diphenhydramine PE=phenylephrine TAN=tannate Brand names are designated in bold in the drug product name column; all other agents are considered generic products..
Recommended publications
  • Table 2. 2012 AGS Beers Criteria for Potentially
    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Brompheniramine Maleate, Pseudoephedrine Hydrochloride
    BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, AND DEXTROMETHORPHAN HYDROBROMIDE- brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup Morton Grove Pharmaceuticals, Inc. ---------- Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Oral Syrup 2 mg/30 mg/10 mg per 5 mL Rx only DESCRIPTION Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup is a clear, light pink syrup with a butterscotch flavor. Each 5 mL (1 teaspoonful) contains: Brompheniramine Maleate, USP 2 mg Pseudoephedrine Hydrochloride, USP 30 mg Dextromethorphan Hydrobromide, USP 10 mg Alcohol 0.95% v/v In a palatable, aromatic vehicle. Inactive Ingredients: artificial butterscotch flavor, citric acid anhydrous, dehydrated alcohol, FD&C Red No. 40, glycerin, liquid sugar, methylparaben, propylene glycol, purified water and sodium benzoate. It may contain 10% citric acid solution or 10% sodium citrate solution for pH adjustment. The pH range is between 3.0 and 6.0. C16H19BrN2·C4H4O4 M.W. 435.31 Brompheniramine Maleate, USP (±)-2-p-Bromo-α-2-(dimethylamino)ethylbenzylpyridine maleate (1:1) C10H15NO · HCl M.W. 201.69 Pseudoephedrine Hydrochloride, USP (+)-Pseudoephedrine hydrochloride C18H25NO · HBr · H2O M.W. 370.32 Dextromethorphan Hydrobromide, USP 3-Methoxy-17-methyl-9α, 13α, 14α -morphinan hydrobromide monohydrate Antihistamine/Nasal Decongestant/Antitussive syrup for oral administration. CLINICAL PHARMACOLOGY Brompheniramine maleate is a
    [Show full text]
  • 2-Bromopyridine Safety Data Sheet Jubilant Ingrevia Limited
    2-Bromopyridine Safety Data Sheet According to the federal final rule of hazard communication revised on 2012 (HazCom 2012) Date of Compilation : July 03 ’ 2019 Date of Revision : February 09 ’ 2021 Revision due date : January 2024 Revision Number : 01 Version Name : 0034Gj Ghs01 Div.3 sds 2-Bromopyridine Supersedes date : July 03 ’ 2019 Supersedes version : 0034Gj Ghs00 Div.3 sds 2-Bromopyridine Jubilant Ingrevia Limited Page 1 of 9 2-Bromopyridine Safety Data Sheet According to the federal final rule of hazard communication revised on 2012 (HazCom 2012) SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1. Product identifier PRODUCT NAME : 2-Bromopyridine CAS RN : 109-04-6 EC# : 203-641-6 SYNONYMS : 2-Pyridyl bromide, Pyridine, 2-bromo-, beta-Bromopyridine, o-Bromopyridine SYSTEMATIC NAME : 2-Bromopyridine, -Pyridine, 2-bromo- MOLECULAR FORMULA : C5H4BrN STRUCTURAL FORMULA N Br 1.2. Relevant identified uses of the substance or mixture and uses advised against 1.2.1. Relevant identified uses 2-Bromopyridine is used as an intermediate in the pharmaceutical industry for the manufacture of Atazanavir (an antiretroviral drug), Carbinoxamine, Chloropyramine, triprolidine (antihistamine drugs), Disopyramide Phosphate (an antiarrythmic drug), Mefloquine (antimalarial drug), Pipradrol (mild CNS stimulant) etc. Uses advised against: None 1.3. Details of the supplier of the safety data sheet Jubilant Ingrevia Limited REGISTERED & FACTORY OFFICE: Jubilant Ingrevia Limited Bhartiagram, Gajraula , District: Amroha, Uttar Pradesh-244223, India PHONE NO: +91-5924-252353 to 252360 Contact Department-Safety: Ext. 7424 , FAX NO : +91-5924-252352 HEAD OFFICE: Jubilant Ingrevia Limited, Plot 1-A, Sector 16-A,Institutional Area, Noida, Uttar Pradesh, 201301 - India T +91-120-4361000 - F +91-120-4234881 / 84 / 85 / 87 / 95 / 96 [email protected] -www.jubilantingrevia.com 1.4.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Medication Instructions for Allergy Patients
    MEDICATION INSTRUCTIONS FOR ALLERGY PATIENTS Drugs which contain antihistamine or have antihistaminic effects can result in negative reactions to skin testing. As a result, it may not be possible to properly interpret skin test results, and testing may have to be repeated at a later date. While this list is extensive, it is NOT all inclusive (particularly of the various brand names). Discontinue ALL antihistamines including the following medications seven (7) days prior to skin testing (unless longer time specified): Antihistamines – Generic name (Brand name(s)): Cetirizine (Zyrtec, Zyrtec-D) Hydroxyzine (Vistaril, Atarax) Desloratadine (Clarinex) Levocetirizine (Xyzal) Fexofenadine (Allegra, Allegra-D) Loratadine (Claritin, Claritin-D, Alavert) Diphenhydramine (Aleve PM, Benadryl, Bayer P.M., Benylin, Contac P.M., Doans P.M, Excedrin PM, Legatrin P.M.. Nytol, Tylenol Nighttime, Unisom, Zzzquil) Chlorpheniramine (Aller-Chlor, Allerest, Alka Seltzer Plus, Chlor-Trimeton, Comtrex, Contac, Co-Pyronil, Coricidin, CTM, Deconamine, Dristan, Dura-tap, Naldecon, Ornade Spansules, Rondec, Sinutab, Teldrin, Triaminic, Triaminicin, Tylenol Allergy) Azatadine (Optimine, Trinalin) Doxylamine (Nyquil) Brompheniramine (Bromfed, Dimetane, Dimetapp) Meclizine (Antivert) Carbinoxamine (Clistin, Rondec) Pheniramine Clemastine (Tavist) Phenyltoloxamine (Nadecon) Cyclizine (Marezine) Promethazine (Phenergan) Cyprohepatidine (Periactin) (9 days) Pyrilamine (Mepyramine) Dexbrompheniramine (Drixoral) Quinacrine (Atabrine) Dexchlorpheniramine (Extendryl, Polaramine)
    [Show full text]
  • The Effect of Bromepheniramine on Cough Sensitivity in Normal Volunteers
    THE EFFECT OF BROMPHENIRAMINE ON COUGH SENSITIVITY IN HEALTHY VOLUNTEERS Haytham M. El-Khushman MD* ABSTRACT Objective: To evaluate the anti-tussive effect of brompheniramine maleate a non-selective, sedative antihistamine using capsaicin challenge. Methods: Twelve subjects, five females and seven females, mean age 32 years with a range of (23-39) years, were studied on two occasions. On the two visits a baseline capsaicin dose-response was performed to determine C5 (the lowest concentration causing 5 coughs). After 30 minutes two C5 doses of capsaicin were given and the total cough over one minute was counted. On the first visit Brompheniramine 8mg or a matched placebo was given orally, and 120, 240 minutes after administration, two C5 doses of capsaicin were given and the total coughs over one minute period were counted. This was repeated exactly in the second visit except subjects received either a placebo or active treatment; either which they had not received on their first visit. Subjects were also asked to quantify their drowsiness using a 100 mm visual analogue scale. Results: Baseline mean cough number (confidence interval) was similar on the two study occasions 9.9 (8.2-11.7) before Brompheniramine and 9.2 (7.3-11.1) before placebo. Cough number did not differ on the two study days at 120 and 240 min after Brompheniramine treatment: 7.7 (5.5-9.8), 7.4 (5.1-9.6) compared to 8.7 (6.4-11.0), 8.3 (6.8- 9.8) after placebo. Mean visual analogue scale (confidence interval) after Brompheniramine was 31 (14-48) and 40 (21-60) compared to 7 (2-12) and 7 (2-12) after Placebo at 120 and 240 min respectively (p<0.008).
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine.
    [Show full text]
  • Antihistamine Therapy in Allergic Rhinitis
    CLINICAL REVIEW Antihistamine Therapy in Allergic Rhinitis Paul R. Tarnasky, MD, and Paul P. Van Arsdel, Jr, MD Seattle, Washington Allergic rhinitis is a common disorder that is associated with a high incidence of mor­ bidity and considerable costs. The symptoms of allergic rhinitis are primarily depen­ dent upon the tissue effects of histamine. Antihistamines are the mainstay of therapy for allergic rhinitis. Recently, a second generation of antihistamines has become available. These agents lack the adverse effect of sedation, which is commonly associated with older antihistamines. Current practice of antihistamine therapy in allergic rhinitis often involves random selection among the various agents. Based upon the available clinical trials, chlorpheniramine appears to be the most reasonable initial antihistaminic agent. A nonsedating antihis­ tamine should be used initially if a patient is involved in activities where drowsiness is dangerous. In this comprehensive review of allergic rhinitis and its treatment, the cur­ rent as well as future options in antihistamine pharmacotherapy are emphasized. J Fam Pract 1990; 30:71-80. llergic rhinitis is a common condition afflicting some­ defined by the period of exposure to those agents to which A where between 15 and 30 million people in the United a patient is sensitive. Allergens in seasonal allergic rhinitis States.1-3 The prevalence of disease among adolescents is consist of pollens from nonflowering plants such as trees, estimated to be 20% to 30%. Two thirds of the adult grasses, and weeds. These pollens generally create symp­ allergic rhinitis patients are under 30 years of age.4-6 Con­ toms in early spring, late spring through early summer, sequently, considerable costs are incurred in days lost and fall, respectively.
    [Show full text]
  • Trends in Prescription Medication Use Among Children and Adolescents— United States, 1999-2014
    Supplementary Online Content Hales CM, Kit BK, Gu Q, Ogden CL. Trends in prescription medication use among children and adolescents— United States, 1999-2014. JAMA. doi:10.1001/jama.2018.5690 eTable. Classification of Prescription Medications Reported by NHANES Participants Aged 0-19 Years From 1999- 2000 to 2013-2014 by Therapeutic Class This supplementary material was provided by the authors to give readers additional informtion about their work. © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 eTable. Classification of Prescription Medications Reported by NHANES Participants Aged 0-19 Years From 1999- 2000 to 2013-2014 by Therapeutic Class Therapeutic classes are based on the Lexicon Plus prescription medication database and only those classes reported in the manuscript are listed. ADHD Medications Antiadrenergic Agents, Centrally Acting Clonidine Guanfacine CNS Stimulants Amphetamines Amphetamine Amphetamine; Dextroamphetamine Dextroamphetamine Lisdexamfetamine Methylphenidate or Dexmethylphenidate Dexmethylphenidate Methylphenidate Other CNS Stimulant Pemoline Selective Norepinephrine Reuptake Inhibitor Atomoxetine Antibiotics Cephalosporins Cefadroxil Cephalexin Cefaclor Cefprozil Cefuroxime Loracarbef Cefdinir Cefditoren Cefixime Cefpodoxime Ceftibuten Ceftriaxone Glycopeptide Antibiotics Vancomycin H. Pylori Eradication Agents Amoxicillin; Clarithromycin; Lansoprazole Lincomycin Derivatives Clindamycin Macrolide Derivatives Telithromycin Azithromycin Clarithromycin
    [Show full text]
  • Medication Guide for a Safe Recovery
    Medication Guide For A Safe Recovery A guide to maintaining sobriety while receiving treatment for other health problems. Revision 1.0 -April 2008 Table of Contents Introduction..................................................................................2 How to Use this Guide..................................................................3 Class A Drugs (Absolutely Avoid)................................................4 Class B Drugs................................................................................8 (With Addiction Medicine Specialist/Doctor Approval Only) Class C Drugs (Generally Safe to Take).....................................12 Alcohol-Free Products..................................................................16 Incidental Exposure Index...........................................................22 www.talbottcampus.com Introduction From the Talbott Recovery Campus Welcome to the Talbott Recovery Campus guide for a safe and sustained recovery. This document was developed through a collaborative effort between some of the best minds in addiction care today and will help you make wise decisions, ensuring that medications you may be prescribed and incidental exposure to alcohol do not threaten your hard won recovery. This guide is divided into three sections and is based on the drug classification system developed nearly 20 years ago by Dr. Paul Earley and recently expanded on by Bruce Merkin, M.D., Renee Enstrom, Nicholas Link and the staff at Glenbeigh hospital. Part one provides a way of categorizing medications
    [Show full text]